Evidence map›Paper›PMID 38933491›Full record

ArticleF1000Research2023

Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.

Panagiotis J Vlachostergios, Maria Papathanassiou, Maria Anagnostou, Eleni Thodou, Ioannis Tamposis, Lampros Mitrakas, Ioannis Zachos, George K Koukoulis, Maria Samara, Vassilios Tzortzis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Panagiotis J VlachostergiosUrology, University of Thessaly, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, Larissa, Thessalia, Greece.ORCID https://orcid.org/0000-0002-1704-1517
Maria PapathanassiouPathology, University of Thessaly, Faculty of Medicine, School of Health Sciences, Larissa, Greece.
Maria AnagnostouPathology, University of Thessaly, Faculty of Medicine, School of Health Sciences, Larissa, Greece.
Eleni ThodouPathology, University of Thessaly, Faculty of Medicine, School of Health Sciences, Larissa, Greece.
Ioannis TamposisComputer Science and Biomedical Informatics, University of Thessaly, Lamia, Greece.ORCID https://orcid.org/0000-0001-9247-6871
Lampros MitrakasUrology, University of Thessaly, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, Larissa, Thessalia, Greece.
Ioannis ZachosUrology, University of Thessaly, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, Larissa, Thessalia, Greece.
George K KoukoulisPathology, University of Thessaly, Faculty of Medicine, School of Health Sciences, Larissa, Greece.
Maria SamaraPathology, University of Thessaly, Faculty of Medicine, School of Health Sciences, Larissa, Greece.
Vassilios TzortzisUrology, University of Thessaly, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, Larissa, Thessalia, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The risk of recurrence after nephrectomy for primary clear cell renal cell carcinoma (ccRCC) is estimated in daily practice solely based on clinical criteria. The aim of this study was to assess the prognostic relevance of common somatic mutations with respect to tumor aggressiveness and outcomes of ccRCC patients after definitive treatment. Methods: Primary tumors from 37 patients with ccRCC who underwent radical nephrectomy were analyzed for presence of somatic mutations using a 15-gene targeted next-generation sequencing (NGS) panel. Associations to histopathologic characteristics and outcomes were investigated in the study cohort (n=37) and validated in The Cancer Genome Atlas (TCGA) ccRCC cohort (n=451). Results: Conclusions: Preliminary findings from this ongoing study support the prognostic value of non-

Indexed as

Carcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsMutationNeoplasm Recurrence, LocalUbiquitin ThiolesteraseAdultAgedAged, 80 and overAtaxia Telangiectasia Mutated ProteinsDNA-Binding ProteinsFemaleHigh-Throughput Nucleotide SequencingHistone DemethylasesHistone-Lysine N-MethyltransferaseHumansAtaxia Telangiectasia Mutated ProteinsATM protein, humanBAP1 protein, humanDNA-Binding ProteinsHistone DemethylasesHistone-Lysine N-MethyltransferaseImmune Checkpoint InhibitorsKDM5C protein, humanNuclear ProteinsPBRM1 protein, humanSETD2 protein, humanTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteinclear cellgenomicsimmune checkpoint inhibitionkidney cancermutational profilenext generation sequencingrecurrencerenal cell carcinoma

Identifiers

PMID38933491
PMCPMC11200057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.